Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 33.31 as of 2026-09-19T00:15:43.163Z.
Consensus retrieved: 2026-09-13T23:00:57.443Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-19T00:15:43.163Z.
Quote observation: 2026-09-18T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16d9fb761af4d4f75fbdea9cd0c33bad22e8ff133c571a16cba71ffd353317c6
Forward PE Ratio (33.31) = Dated Quote Price ($125.31) / Consensus Forward EPS ($3.76)
FORWARD PE RATIO
33.31
SECTOR MEDIAN · HEALTHCARE
18.84
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+76.76%
vs the sector median at left
Incyte Corporation
Market Cap
$25.40B
Forward PE Ratio
33.31
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Incyte Corporation (INCY) | $25.40B | 33.31 |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.49B | 40.39 |
| Labcorp Holdings Inc. (LH)vs › | $26.30B | 17.48 |
| BioNTech SE (BNTX)vs › | $24.13B | N/A |
| Medline Inc. (MDLN)vs › | $26.75B | 21.20 |
| Quest Diagnostics Incorporated (DGX)vs › | $27.20B | 22.02 |
| Mettler-Toledo International Inc. (MTD)vs › | $28.14B | 29.42 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $28.97B | 13.02 |
| United Therapeutics Corporation (UTHR)vs › | $21.00B | 18.92 |
| Zoetis Inc. (ZTS)vs › | $29.95B | 11.43 |
Trailing P/E
16.0
reported TTM EPS
Forward P/E
33.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.76 implies -52.1% EPS decline vs the reported trailing $7.85.
At the dated quote price of $125.31, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.76 | $2.80 – $4.49 | 13 | 33.3x |
| 2027-12-31 | $8.54 | $7.30 – $10.57 | 15 | 14.7x |
| 2028-12-31 | $9.09 | $6.60 – $11.76 | 12 | 13.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
